Persistent competition in key therapeutic areas, headwinds from lower COVID-19 product revenues and rising threats on the US drug pricing front are putting more pressure on new brands to deliver future growth for big pharmaceutical companies.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on In Vivo for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?